Penn Medicine Researchers Pinpoint Potential New Drug Target for Protection against Certain Neurodegenerative Diseases
Findings Could Pave Way for Precision Medicine Approach to Treatment of Neurological Diseases.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases. Their work, published this month in Neurology, may suggest a neuroprotective target for drug discovery efforts.
IOA in the News
The Sylvan M. Cohen 2015 Annual Retreat
"Aging with Financial Security: Addressing the Challenges of Cognitive Aging and Impairment"
Tuesday, May 5, 2015 | 11:30am - 5:00pm
Smilow Center | 3400 Civic Center Boulevard, Philadelphia, PA 19104
More info: Details on registration, the poster session, and the event's agenda available here.
Poster Submission: Submit a poster here.
Join the nearly 300 Institute on Aging Fellows and Associate Fellows and experience robust collaborative opportunities in aging at Penn, for funding opportunity alerts, pilot research grant opportunities, and updates on IOA activities.Get Involved
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team